Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,954.00
(
-0.25%
)
Dow Jones
46,946.41
(
0.00%
)
Brent Oil
100.10
(
1.83%
)
Bitcoin
74,097.45
(
-1.00%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 114841

Tuesday, 02/15/2011 7:48:59 PM

Tuesday, February 15, 2011 7:48:59 PM

Post# of 257251
From the same article:

A year ago, the company was lucky to be selling $5 million a year in products.

Actually, a year ago MNTA was not selling anything—its revenue was from in-house R&D reimbursed by NVS.

The trajectory of the profit performance is remarkable, reports Robert Auer, senior portfolio manager of the SBAuer Funds.

Well, duh, that kind of thing can happen when a drug is approved for marketing. Geez.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today